Japanese drugmaker wins fees in cancer drug feud

Japanese drugmaker wins fees in cancer drug feud

Japan’s Daiichi Sankyo says it has been awarded almost US$46 million in fees and costs after prevailing in an ICDR arbitration with US biotech group Seagen over rights to technology used in cancer medicines.

Unlock unlimited access to all Global Arbitration Review content